IL-12 Induces the Capability of A-LAK Cells to Kill Autologous DCs When CD28 Is Expressed on the Effector Cell Population
| E:T | % Specific Lysis* | ||||||||
| Experiment 1 | Experiment 2 | ||||||||
| C57BL/6 | CD28−/− | C57BL/6 | CD28−/− | ||||||
| IL-2 | IL-2/12 | IL-2 | IL-2/12 | IL-2 | IL-2/12 | IL-2 | IL-2/12 | ||
| Spleen DCs | 20:1 | 10 (±2) | 20 (±1) | 0 (±3) | 3 (±0) | 5 (±2) | 25 (±3) | 1 (±5) | 0 (±2) |
| 10:1 | 3 (±2) | 15 (±1) | 2 (±0) | 0 (±3) | 1 (±2) | 16 (±4) | 0 (±5) | 0 (±2) | |
| 5:1 | 4 (±6) | 14 (±1) | 2 (±2) | 0 (±2) | 0 (±1) | 13 (±2) | 0 (±5) | 0 (±2) | |
| 2.5:1 | 1 (±2) | 12 (±2) | 1 (±2) | 0 (±1) | 1 (±7) | 12 (±1) | 0 (±4) | 0 (±2) | |
| Progenitor DCs | 20:1 | ND | ND | ND | ND | 4 (±1) | 23 (±1) | 1 (±0) | 6 (±2) |
| 10:1 | ND | ND | ND | ND | 1 (±1) | 18 (±3) | 0 (±1) | 5 (±2) | |
| 5:1 | ND | ND | ND | ND | 2 (±1) | 10 (±1) | 0 (±1) | 1 (±2) | |
| 2.5:1 | ND | ND | ND | ND | 2 (±1) | 9 (±1) | 0 (±1) | 2 (±1) | |
| YAC-1† | 20:1 | 43 (±3) | 44 (±2) | 19 (±1) | 25 (±2) | 70 (±1) | 72 (±2) | 40 (±3) | 49 (±1) |
| 10:1 | 29 (±1) | 36 (±2) | 14 (±1) | 18 (±1) | 58 (±1) | 61 (±1) | 29 (±1) | 39 (±2) | |
| 5:1 | 22 (±1) | 28 (±1) | 8 (±1) | 17 (±3) | 46 (±0) | 52 (±3) | 19 (±1) | 30 (±1) | |
| 2.5:1 | 13 (±0) | 19 (±2) | 5 (±0) | 8 (±1) | 34 (±1) | 43 (±1) | 12 (±0) | 21 (±0) | |
| E:T | % Specific Lysis* | ||||||||
| Experiment 1 | Experiment 2 | ||||||||
| C57BL/6 | CD28−/− | C57BL/6 | CD28−/− | ||||||
| IL-2 | IL-2/12 | IL-2 | IL-2/12 | IL-2 | IL-2/12 | IL-2 | IL-2/12 | ||
| Spleen DCs | 20:1 | 10 (±2) | 20 (±1) | 0 (±3) | 3 (±0) | 5 (±2) | 25 (±3) | 1 (±5) | 0 (±2) |
| 10:1 | 3 (±2) | 15 (±1) | 2 (±0) | 0 (±3) | 1 (±2) | 16 (±4) | 0 (±5) | 0 (±2) | |
| 5:1 | 4 (±6) | 14 (±1) | 2 (±2) | 0 (±2) | 0 (±1) | 13 (±2) | 0 (±5) | 0 (±2) | |
| 2.5:1 | 1 (±2) | 12 (±2) | 1 (±2) | 0 (±1) | 1 (±7) | 12 (±1) | 0 (±4) | 0 (±2) | |
| Progenitor DCs | 20:1 | ND | ND | ND | ND | 4 (±1) | 23 (±1) | 1 (±0) | 6 (±2) |
| 10:1 | ND | ND | ND | ND | 1 (±1) | 18 (±3) | 0 (±1) | 5 (±2) | |
| 5:1 | ND | ND | ND | ND | 2 (±1) | 10 (±1) | 0 (±1) | 1 (±2) | |
| 2.5:1 | ND | ND | ND | ND | 2 (±1) | 9 (±1) | 0 (±1) | 2 (±1) | |
| YAC-1† | 20:1 | 43 (±3) | 44 (±2) | 19 (±1) | 25 (±2) | 70 (±1) | 72 (±2) | 40 (±3) | 49 (±1) |
| 10:1 | 29 (±1) | 36 (±2) | 14 (±1) | 18 (±1) | 58 (±1) | 61 (±1) | 29 (±1) | 39 (±2) | |
| 5:1 | 22 (±1) | 28 (±1) | 8 (±1) | 17 (±3) | 46 (±0) | 52 (±3) | 19 (±1) | 30 (±1) | |
| 2.5:1 | 13 (±0) | 19 (±2) | 5 (±0) | 8 (±1) | 34 (±1) | 43 (±1) | 12 (±0) | 21 (±0) | |
*The percent specific lysis (±SD) was determined in standard 4-hour 111In-release cytotoxicity experiments. Spontaneous release was < 3% for YAC-1, <12% for progenitor DCs, and <35% for spleen DCs. Both experiments were performed in triplicates and repeated three times.
The specific lysis of YAC-1 cells was used as a reference for the overall lytic capability of C57BL/6 versus CD28−/−–derived IL-2 and IL-2/IL-12 A-LAK cultures.